BOLT
Bolt Biotherapeutics, Inc.
Price Chart
Latest Quote
$6.30
-0.29 (-4.40%)
Current Price
| Previous Close | $6.59 |
| Open | $6.58 |
| Day High | $6.64 |
| Day Low | $6.22 |
| Volume | 140,085 |
Stock Information
| Shares Outstanding | 2.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.85M |
| EPS (TTM) | $-16.51 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Book/sh | $6.56 |
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 2.58% |
| Institutional Ownership | 20.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.31 |
| P/B | 0.96 |
Analyst Data
| Recommendation | buy |
| Target Price | $41.00 |
Technical Indicators
| SMA20 | $4.28 |
| SMA50 | $3.94 |
| SMA200 | $4.50 |
| RSI | 78.66 |
| ATR | 0.6591 |
| Short Float | 1.34% |
| Short Ratio | 0.72 |
| Rel Volume | 0.20 |
Performance History
| Week | +46.17% |
| Month | +82.08% |
| Quarter | +63.64% |
| 6 Months | +30.17% |
| YTD | +8.81% |
| Year | +5.00% |
| 3 Years | -69.42% |
| 5 Years | -97.53% |
| 10 Years | -99.02% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $6.30 | 140,085 |
| 2026-10-26 | $6.59 | 419,100 |
| 2026-10-23 | $6.27 | 12,882,700 |
| 2026-10-22 | $4.19 | 14,100 |
| 2026-10-21 | $4.14 | 34,500 |
| 2026-10-20 | $4.31 | 29,300 |
| 2026-10-19 | $4.04 | 21,900 |
| 2026-10-16 | $4.00 | 10,100 |
| 2026-10-15 | $4.24 | 9,300 |
| 2026-10-14 | $3.98 | 31,100 |
| 2026-10-13 | $4.28 | 12,800 |
| 2026-10-12 | $4.24 | 28,700 |
| 2026-10-09 | $4.11 | 87,200 |
| 2026-10-08 | $3.65 | 10,500 |
| 2026-10-07 | $3.60 | 54,000 |
| 2026-10-06 | $3.51 | 23,300 |
| 2026-10-05 | $3.50 | 9,800 |
| 2026-10-02 | $3.45 | 900 |
| 2026-10-01 | $3.51 | 21,700 |
| 2026-09-30 | $3.68 | 9,300 |
| 2026-09-29 | $3.60 | 9,500 |
| 2026-09-28 | $3.46 | 19,900 |
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BOLT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,695,000 | $7,690,000 | $7,876,000 | $5,729,000 |
| Operating Revenue | $7,695,000 | $7,690,000 | $7,876,000 | $5,729,000 |
| Expenses | ||||
| Total Expenses | $42,328,000 | $75,926,000 | $84,072,000 | $96,050,000 |
| Other Income Expense | $-1,239,000 | $-137,000 | - | - |
| Other Non Operating Income Expenses | $241,000 | $4,675,000 | - | - |
| Net Non Operating Interest Income Expense | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Operating Expense | $42,328,000 | $75,926,000 | $84,072,000 | $96,050,000 |
| General And Administrative Expense | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Interest Income | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Interest Income | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Normalized Income | $-31,896,000 | $-58,306,000 | $-69,197,000 | $-88,098,000 |
| Net Income From Continuing And Discontinued Operation | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Total Operating Income As Reported | $-36,113,000 | $-73,048,000 | $-76,196,000 | $-90,321,000 |
| Net Income Common Stockholders | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income Including Noncontrolling Interests | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Net Income Continuous Operations | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Pretax Income | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Special Income Charges | $-1,480,000 | $-4,812,000 | $0 | - |
| Interest Income Non Operating | $2,496,000 | $5,255,000 | $6,999,000 | $2,223,000 |
| Operating Income | $-34,633,000 | $-68,236,000 | $-76,196,000 | $-90,321,000 |
| Per Share | ||||
| Diluted EPS | $-17.85 | $-33.00 | $-36.60 | $-47.20 |
| Basic EPS | $-17.85 | $-33.00 | $-36.60 | $-47.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-31,862,000 | $-61,643,000 | $-74,342,000 | $-88,655,000 |
| Total Unusual Items | $-1,480,000 | $-4,812,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-1,480,000 | $-4,812,000 | $0 | - |
| Reconciled Depreciation | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| EBITDA (Bullshit earnings) | $-33,342,000 | $-66,455,000 | $-74,342,000 | $-88,655,000 |
| EBIT | $-34,633,000 | $-68,236,000 | $-76,196,000 | $-90,321,000 |
| Diluted Average Shares | $1,869,924 | $1,909,196 | $1,890,599 | $1,867,921 |
| Basic Average Shares | $1,869,924 | $1,909,196 | $1,890,599 | $1,867,921 |
| Diluted NI Availto Com Stockholders | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Write Off | $0 | $1,469,000 | $0 | - |
| Impairment Of Capital Assets | $0 | $1,469,000 | $0 | - |
| Restructuring And Mergern Acquisition | $1,480,000 | $3,343,000 | $0 | - |
| Research And Development | $28,533,000 | $57,469,000 | $61,542,000 | $73,123,000 |
| Selling General And Administration | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Other Gand A | $13,795,000 | $18,457,000 | $22,530,000 | $22,927,000 |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-10-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Total Assets | $56,748,000 | $99,632,000 | $159,784,000 | $227,807,000 |
| Total Non Current Assets | $26,488,000 | $48,818,000 | $54,076,000 | $55,061,000 |
| Other Non Current Assets | $1,676,000 | $1,043,000 | $3,586,000 | $2,593,000 |
| Investmentin Financial Assets | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Current Assets | $30,260,000 | $50,814,000 | $105,708,000 | $172,746,000 |
| Other Current Assets | $653,000 | $509,000 | $1,086,000 | $3,858,000 |
| Restricted Cash | $200,000 | $784,000 | $0 | - |
| Prepaid Assets | $929,000 | $1,033,000 | $906,000 | - |
| Receivables | $973,000 | $1,165,000 | $1,527,000 | - |
| Other Receivables | $973,000 | $1,165,000 | $1,527,000 | - |
| Cash Cash Equivalents And Short Term Investments | $27,505,000 | $47,323,000 | $102,189,000 | $168,888,000 |
| Cash And Cash Equivalents | $11,703,000 | $7,205,000 | $10,810,000 | $9,244,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $22,958,000 | $25,209,000 | $20,219,000 | $22,611,000 |
| Long Term Debt And Capital Lease Obligation | $20,132,000 | $22,958,000 | $17,437,000 | $20,220,000 |
| Current Debt And Capital Lease Obligation | $2,826,000 | $2,251,000 | $2,782,000 | $2,391,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,243,000 | $42,434,000 | $47,043,000 | $56,301,000 |
| Total Non Current Liabilities Net Minority Interest | $21,808,000 | $26,578,000 | $26,587,000 | $33,183,000 |
| Other Non Current Liabilities | $132,000 | - | $43,000 | $42,000 |
| Non Current Deferred Liabilities | $1,544,000 | $3,620,000 | $9,107,000 | $12,921,000 |
| Current Liabilities | $8,435,000 | $15,856,000 | $20,456,000 | $23,118,000 |
| Current Deferred Liabilities | $449,000 | $3,015,000 | $2,201,000 | $1,993,000 |
| Payables And Accrued Expenses | $3,518,000 | $6,387,000 | $9,653,000 | $13,930,000 |
| Payables | $1,443,000 | $1,507,000 | $2,987,000 | $3,594,000 |
| Accounts Payable | $1,443,000 | $1,507,000 | $2,987,000 | $3,594,000 |
| Equity | ||||
| Common Stock Equity | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Total Equity Gross Minority Interest | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Stockholders Equity | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Gains Losses Not Affecting Retained Earnings | $-21,000 | $97,000 | $37,000 | $-919,000 |
| Other Equity Adjustments | $-21,000 | $97,000 | $37,000 | $-919,000 |
| Retained Earnings | $-460,779,000 | $-427,403,000 | $-364,285,000 | $-295,088,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $1,920,566 | $1,916,984 | $1,905,730 | $1,889,895 |
| Share Issued | $1,920,566 | $1,916,984 | $1,905,730 | $1,889,895 |
| Tangible Book Value | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Invested Capital | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Working Capital | $21,825,000 | $34,958,000 | $85,252,000 | $149,628,000 |
| Capital Lease Obligations | $22,958,000 | $25,209,000 | $20,219,000 | $22,611,000 |
| Total Capitalization | $26,505,000 | $57,198,000 | $112,741,000 | $171,506,000 |
| Additional Paid In Capital | $487,305,000 | $484,504,000 | $476,989,000 | $467,513,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,544,000 | $3,620,000 | $9,107,000 | $12,921,000 |
| Long Term Capital Lease Obligation | $20,132,000 | $22,958,000 | $17,437,000 | $20,220,000 |
| Current Deferred Revenue | $449,000 | $3,015,000 | $2,201,000 | $1,993,000 |
| Current Capital Lease Obligation | $2,826,000 | $2,251,000 | $2,782,000 | $2,391,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,642,000 | $4,203,000 | $5,820,000 | $4,804,000 |
| Current Accrued Expenses | $2,075,000 | $4,880,000 | $6,666,000 | $10,336,000 |
| Investments And Advances | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Available For Sale Securities | $4,337,000 | $22,880,000 | $26,413,000 | $23,943,000 |
| Net PPE | $20,475,000 | $24,895,000 | $24,077,000 | $28,525,000 |
| Accumulated Depreciation | $-7,387,000 | $-7,278,000 | $-5,752,000 | $-3,915,000 |
| Gross PPE | $27,862,000 | $32,173,000 | $29,829,000 | $32,440,000 |
| Leases | $358,000 | $286,000 | $285,000 | $272,000 |
| Other Properties | $27,118,000 | $31,501,000 | $29,158,000 | $31,810,000 |
| Machinery Furniture Equipment | $386,000 | $386,000 | $386,000 | $358,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $15,802,000 | $40,118,000 | $91,379,000 | $159,644,000 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | $0 | $0 |
Fetched: 2026-10-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,922,000 | $-61,330,000 | $-69,731,000 | $-78,457,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,850,000 | $-61,289,000 | $-69,525,000 | $-76,504,000 |
| Cash Flow From Continuing Operating Activities | $-39,850,000 | $-61,289,000 | $-69,525,000 | $-76,504,000 |
| Operating Gains Losses | $-288,000 | $-70,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-72,000 | $-41,000 | $-206,000 | $-1,953,000 |
| Investing Cash Flow | $44,302,000 | $57,576,000 | $71,038,000 | $57,862,000 |
| Cash Flow From Continuing Investing Activities | $44,302,000 | $57,576,000 | $71,038,000 | $57,862,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,000 | $108,000 | $253,000 | $503,000 |
| Financing Cash Flow | $19,000 | $108,000 | $253,000 | $503,000 |
| Cash Flow From Continuing Financing Activities | $19,000 | $108,000 | $253,000 | $503,000 |
| Net Common Stock Issuance | $19,000 | $108,000 | $253,000 | $503,000 |
| Common Stock Issuance | $19,000 | $108,000 | $253,000 | $503,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $13,441,000 | $8,970,000 | $12,575,000 | $10,809,000 |
| Beginning Cash Position | $8,970,000 | $12,575,000 | $10,809,000 | $28,948,000 |
| Changes In Cash | $4,471,000 | $-3,605,000 | $1,766,000 | $-18,139,000 |
| Net Investment Purchase And Sale | $43,411,000 | $57,469,000 | $71,244,000 | $59,815,000 |
| Sale Of Investment | $72,427,000 | $146,324,000 | $236,232,000 | $240,519,000 |
| Purchase Of Investment | $-29,016,000 | $-88,855,000 | $-164,988,000 | $-180,704,000 |
| Net PPE Purchase And Sale | $891,000 | $107,000 | $-206,000 | $-1,953,000 |
| Sale Of PPE | $963,000 | $148,000 | $0 | - |
| Purchase Of PPE | $-72,000 | $-41,000 | $-206,000 | $-1,953,000 |
| Change In Working Capital | $-12,115,000 | $-8,440,000 | $-9,864,000 | $-3,057,000 |
| Change In Other Working Capital | $-4,642,000 | $-4,673,000 | $-3,606,000 | $-2,162,000 |
| Change In Other Current Liabilities | $-2,119,000 | $-1,455,000 | $-2,391,000 | $-2,760,000 |
| Change In Payables And Accrued Expense | $-5,430,000 | $-4,883,000 | $-3,413,000 | $2,768,000 |
| Change In Prepaid Assets | $76,000 | $2,571,000 | $-454,000 | $-903,000 |
| Other Non Cash Items | $2,526,000 | $2,297,000 | $2,952,000 | $3,225,000 |
| Stock Based Compensation | $2,782,000 | $7,407,000 | $9,223,000 | $9,576,000 |
| Asset Impairment Charge | $0 | $1,469,000 | $0 | - |
| Amortization Of Securities | $-670,000 | $-2,615,000 | $-4,493,000 | $184,000 |
| Depreciation Amortization Depletion | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| Depreciation And Amortization | $1,291,000 | $1,781,000 | $1,854,000 | $1,666,000 |
| Gain Loss On Sale Of PPE | $-288,000 | $-70,000 | $0 | $0 |
| Net Income From Continuing Operations | $-33,376,000 | $-63,118,000 | $-69,197,000 | $-88,098,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-10-06